Skip to main content

Find Clinical Trials

Home
Conditions
EGFR Gene Mutation

Clinical trial condition

EGFR Gene Mutation

Explore clinical trials studying EGFR Gene Mutation. Study availability and eligibility vary by location and protocol.

41 public trials 14 recruiting studies

Refine in advanced search Browse all conditions

EGFR Gene Mutation trial results

Recruiting

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890

Conditions: ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +12 more
Locations: Yongchang Zhang Changsha, Hunan, China

View Trial Details

Recruiting

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

NCT04085315

Conditions: EGFR Gene Mutation, Lung Cancer Metastatic
Locations: University of California, San Francisco San Francisco, California, United States

View Trial Details

Recruiting

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

NCT05503667

Conditions: Adenocarcinoma, Adenocarcinoma of Lung, Carcinoma, +10 more
Locations: Shanghai Pulmonary Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

NCT05033691

Conditions: Brain Diseases, Brain Metastases, Brain Neoplasms, +18 more
Locations: Hadassah Ein Kerem Medical Center Jerusalem, Israel

View Trial Details

Not Yet Recruiting

In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing

NCT07697716

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

NCT07461727

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

NCT06436144

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

NCT06323148

Conditions: EGFR Gene Mutation, Lung Cancer, Lung Diseases, +11 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

NCT06117644

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

NCT06018688

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations: Not specified

View Trial Details